Importance and extent of phlebological health care in dermatological practices

Summary

Background: Venous diseases are of great socio-economic importance in Germany. Question: What is the scope and importance of phlebological care by office-based dermatologists? Methods: Structured online survey in May 2018 in n = 1,500 dermatological practices nationwide. Results: Of the 704 (46.9%) practices, 49.7% have additional certified qualification in phlebology. 87% of dermatologists carry out phlebological treatments, 74% of which are based on contracts with the statutory health insurances. On average they treat 18 phlebological patients per week and 880 per year, respectively. Most frequent procedures: Vein diagnostics (Doppler/duplex) and sclerosis of spider veins or lateral branches (each > 50%). 43% were rather or very satisfied with their phlebological treatment options, 35% assessed the care situation in phlebology worse than 10 years ago. Certified qualification in phlebology is considered to be of great importance by 82%. Conclusion: Specialized phlebological care as well as the additional certificate „phlebology“, are mostly considered as important for dermatology as a specialty.

Keywords

Health care - phlebology - survey - qualification - certification

Interessenkonflikt

Nach Angaben der Autoren bestehen keine Interessenkonflikte.

• Literatur

• 1 Augustin M, Sommer R, Zander N. et al. Epidemiologie, Versorgungsbedarf und Versorgungsvolumina peripherer Venenkrankheiten in Deutsch-land: Multi-Source Analyse von Primär- und Sekundärdaten.. Phlebologie. 2018 doi: 10.12687/phleb2440–5–2018.
• 2 Eklöf B, Rutherford RB, Bergan JJ. et al. Wakefield, Revision of the CEAP classification for chronic venous disorders: Consensus statement.. Journal of Vascular Surgery 2004; 40: 1248-1252.
• 3 Stücker M, Debus ES, Hoffmann J. et al. Consensus statement on the symptom-based treatment of chronic venous diseases.. J Dtsch Dermatol Ges 2016; 14: 575-83.
• 4 GBE-Bund. http://www.gbe-bund.de/oowa921-install/servlet/oowa/aw92/dboowasys921.xwdevkit/xwd_init?gbe.isgbetol/xs_start_neu&p_aid=i&p_aid=33954832&nummer=612&p_s prache=D&p_indsp=93&p_aid=42395654. Zugriff 30.04.2018
• 5 Rabe E, Pannier-Fischer F, Bromen K. et al. Bonner Venenstudie der Deutschen Gesellschaft für Phlebologie – Epidemiologische Untersuchung zur Frage der Häufigkeit und Ausprägung von chronischen Venenkrankheiten in der städtischen und ländlichen Wohnbevölkerung.. Phlebologie 2003; 32: 1-14.
• 6 Kemper C, Sauer K, Glaeske G.. Barmer GEK Heilund Hilfsmittelreport 2011. Auswertungsergebnisse der BARMER GEK Heil- und Hilfsmitteldaten aus den Jahren 2009 bis 2010.. Schriftenreihe zur Gesundheitsanalyse; Band: 10 2011
• 7 Augustin M, Debus ES, Bruning G. et al. Development and Validation of a Short Version of the Freiburg Life Quality Assessment for Chronic Venous Disease (FLQA-VS-10).. Wound Medicine 2015; 8: 31-35.
• 8 Zschocke I, Bross F, Maier K. et al. Quality of Life in Different Stages of Chronic Venous Insufficiency and Leg Ulcer.. Dermatol Psychosom 2002; 3: 126-131.
• 9 Augustin M, Dieterle W, Zschocke I. et al. Development and Validation of a Disease Specific Questionnaire on the Quality of Life of Patients with Chronic Venous Insufficiency.. Vasa 1997; 26: 291-301.
• 10 Sommer R, Augustin M, Blome C.. Erfassung von Lebensqualität und Verwendung patientenberichteter Endpunkte in der Praxis.. Phlebologie 2017; 46: 334-339.
• 11 Purwins S, Herberger K, Debus ES. et al. Cost-of-illness of chronic leg ulcers in Germany.. Int Wound J 2010; 7: 7-102.
• 12 Augustin M, Brocatti LK, Rustenbach SJ. et al. Cost-of-illness of leg ulcers in the community 2014; 11: 283-92.
• 13 Heyer K, Protz K, Glaeske G, Augustin M.. Epidemiology and Use of Compression Treatment in Venous Leg Ulcers: Nationwide Claims Data Analysis in Germany.. Int Wound J 2016; 14: 338-343.
• 14 Heyer K, Protz K, Augustin M.. Compression Therapy – Cross-sectional Observational Survey About Knowledge and Practical Treatment of Specialised and Non-specialised Nurses and Therapists.. Int Wound J 2017; 14: 1148-1153.